Cambridge Healthtech Institute’s Inaugural

Cancer Immunotherapy

Emerging Biology, Targets and Strategies

March 7 – 9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

 

Cancer immunotherapy, hailed as the biggest breakthrough in modern cancer treatment, has quickly permeated mainstream basic and clinical research. With vast excitement seen over the past few years stirred by remarkable clinical efficacy of immunotherapy agents, the emergence and rapid growth of biotechs and pharmaceutical partnering, and recent regulatory approvals of checkpoint inhibitors and T-cell engagers, it has become clear that immuno-oncology research and the development of immunotherapies and their combinations will continue to revolutionize cancer treatment. 

Cambridge Healthtech Institute’s inaugural Cancer Immunotherapy meeting will convene immuno-oncology researchers, cancer immunotherapy developers, and technology providers to discuss current challenges and opportunities - from discovery immuno-oncology to clinical studies; share latest technologies and development approaches; discuss advances in adoptive T-cell therapies and combinations, as well as to provide updates on clinical findings.

Preliminary Agenda


HARNESSING NK CELLS FOR NEW ADOPTIVE CELL THERAPIES

Enhancing NK Cell Function for Transplantation and Cancer Therapy

Jeffrey Miller, M.D., Professor, Medicine; Deputy Director; Roger L. and Lynn C. Headrick Chair in Cancer Therapeutics, University of Minnesota Cancer Center

Innate Immune Defenses Against Cancer

David H. Raulet, Ph.D., CH Li Professor of Immunology and Pathogenesis; Co-Chair, Department of Molecular and Cell Biology, University of California, Berkley

Basic and Translational Natural Killer (NK) Cell Biology

Todd A. Fehniger, M.D., Ph.D., Associate Professor, Department of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia Section, Washington University School of Medicine


ADVANCES IN ADOPTIVE T-CELL THERAPY

Rational Development and Characterization of Humanized Anti-EGFR Variant III Chimeric Antigen Receptor T-Cells for Glioblastoma

Marcela Valderrama Maus, M.D., Ph.D., Assistant Professor, Medicine; Director, Medical Affairs, Translational Research Program, Abramson Cancer Center, University of Pennsylvania

The ImmTAC Technology: A Cutting Edge Immunotherapy for Cancer Treatment

Martina Canestraro, Ph.D., Scientist, Cell biology, Immunocore Limited


EMERGING STRATEGIES FOR CHECKPOINT COMBINATION THERAPY

Cyclic Dinucleotides and Cancer Vaccine Development

Thomas W. Dubensky, Jr., Ph.D., CSO, Aduro Biotech

OX40 Agonist Combined with PD-1 and TGFb Receptor Blockade

Andrew D. Weinberg, Ph.D., Chief, Laboratory of Basic Immunology, Providence Cancer Center

Pre-Clinical Evaluation of an Agonist Antibody Targeting ICOS

Robert Mabry, Ph.D., Director, Protein Sciences and Antibody Technology, Jounce Therapeutics

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells

John C. Lin, Ph.D., Senior Vice President & CSO, Cancer Immunotherapy, Pfizer

Combination Immunotherapies – Opening the Gate: Increasing Tumor Infiltrating Activated T-Cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies

Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals


NOVEL AND EMERGING TARGETS

Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1

Xingxing Zang, Ph.D., Associate Professor, Microbiology, Immunology and Medicine, Albert Einstein College of Medicine

oxMIF as a New Therapeutic Target in Cancer

Michael Thiele, Ph.D., Manager R&D, Research & Innovation, Baxalta Innovations GmbH


TECHNOLOGICAL INNOVATIONS ENABLING DISCOVERY

New Insight into Mode of Action of Checkpoint Inhibitors via QC Cell Based Assays

Natko Nuber, Ph.D., Lab head, Novartis Biologics, Novartis

Presentation to be Announced

Sponsored by Oncodesign

Presentation to be Announced

Sponsored by Charles River

 

Premier Sponsors:  

Bina Technologies

Coyote

Elsevier   

Jackson Laboratory - small logo 

 NanoString2   

 Precision for Medicine 

SeraCare(2)

Silicon Biosystems

Thomson Reuters-Large